Cybin Corp., an exemplary Canada-based, life-science company focused on the development of pharmaceutical-grade psilocybin products, is at the forefront of change in an era open to exploring psychedelic treatment options where big pharma has failed. Started in the 1940s, but kiboshed in the 1960s with President Richard Nixon’s war on drugs, researchers have once again picked up the study of psychedelics in the treatment of mental health conditions. Research is showing positive results for many indications and disorders including depression, anxiety, PTSD, addictions, ADHD and more. A recent article discussing this reads, “Cybin believes that psychedelic substances derived from mushrooms can work as boosters for the brain, potentially rebuilding pathways and breaking negative patterns. Today more than 700 million people around the world struggle with mental illness, addiction or eating disorders — all areas where the benefits of psychedelic substances is being studied. What’s more, even though over 40 million Americans are taking psychiatric drugs, big pharma has not produced any new drug innovations in the last ten years (http://ibn.fm/f8BH4).”
To view the full article, visit http://ibn.fm/TTY8F
About Cybin Corp.
Cybin is a mushroom life-science company advancing psychedelic and nutraceutical-based products. The company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the company is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships. For more information, visit www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
